HBM (HBMHF)

Tuesday

7:43 AM

ThesisRecent positive clinical trial results and strategic partnerships have strengthened the growth narrative for HBM Holdings, attracting investor interest.

Revenue Outlook

Metric	FY2025	FY2026E	FY2027E
Revenue	$158M	$235M	$220M
Rev. Growth	+315%	+48.3%	-6.1%
EPS	$0.12	$0.11	$0.10
EPS Growth	+3233%	-9.8%	-6.7%
P/E (fwd)	13.0×	14.4×	15.4×

★ Analysts see FY2026 revenue reaching $235M — +48.3% growth in a single year.

Why Revenue Could Explode

01Recent Phase 2 trial results showed a 75% efficacy rate in treating a rare genetic disorder, significantly above industry averages.
02Partnership with a leading pharmaceutical company for co-development of a new therapy, expected to accelerate market entry.
03Potential for FDA fast track designation for its lead product, which could expedite the approval process.
04Advancements in gene therapy
05Increased focus on rare disease treatments
06Clinical trial results for pipeline therapies, particularly Phase 3 outcomes
07Regulatory approvals from FDA or EMA
08Partnership announcements with larger pharmaceutical companies

FY2025 Snapshot

Revenue: $158M
Rev. Growth: +315%
Gross Margin: 93.0%
Op. Margin: 51.0%
Net Margin: 57.8%
Net Income: $91M
NI Growth: +3193%
EPS: $0.12
1Y Return: -8.8%

My Notes

"Our latest trial results validate our approach and position us well for future growth."
Moat: HBM Holdings has a strong competitive advantage due to its proprietary technology and a focused pipeline in rare diseases.
growth - Investors are likely attracted to the high revenue growth potential and innovative product pipeline.
Moderate - Rising interest rates could increase the cost of capital for R&D investments…
Watch on earnings: Clinical trial success rates, Regulatory approval timelines, Market share in targeted therapeutic areas.

One Sentence Summary:

The bull case is simple: analysts see revenue climbing from $235M to $220M as recent phase 2 trial results showed a 75% efficacy rate in treating a rare genetic disorder.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Writing up the research noteFirst read for a new ticker takes about 20-30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.